Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Optimizerx Corp (OPRX)

Optimizerx Corp (OPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 172,056
  • Shares Outstanding, K 18,641
  • Annual Sales, $ 92,130 K
  • Annual Income, $ -18,660 K
  • EBIT $ 11 M
  • EBITDA $ 16 M
  • 60-Month Beta 1.18
  • Price/Sales 1.59
  • Price/Cash Flow N/A
  • Price/Book 1.54

Options Overview Details

View History
  • Implied Volatility 152.26% (+1.13%)
  • Historical Volatility 70.93%
  • IV Percentile 99%
  • IV Rank 99.52%
  • IV High 152.71% on 02/10/26
  • IV Low 58.91% on 05/30/25
  • Expected Move (DTE 8) 0.09 (1.01%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 25
  • Volume Avg (30-Day) 256
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 4,643
  • Open Int (30-Day) 3,944
  • Expected Range 8.36 to 8.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.11
  • Number of Estimates 4
  • High Estimate 0.13
  • Low Estimate 0.09
  • Prior Year 0.14
  • Growth Rate Est. (year over year) -21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.28 +0.91%
on 02/12/26
14.13 -40.84%
on 01/13/26
-5.70 (-40.54%)
since 01/12/26
3-Month
8.28 +0.91%
on 02/12/26
16.37 -48.93%
on 11/13/25
-7.79 (-48.24%)
since 11/12/25
52-Week
3.99 +109.45%
on 03/11/25
22.25 -62.43%
on 10/27/25
+2.77 (+49.55%)
since 02/12/25

Most Recent Stories

More News
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and...

OPRX : 8.24 (-10.73%)
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing

WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and...

OPRX : 8.24 (-10.73%)
OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network

WALTHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and...

OPRX : 8.24 (-10.73%)
AI Spending in Healthcare and Wellness Triples as Personalized Wellness Platforms Scale

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – Healthcare's artificial intelligence transformation is accelerating at unprecedented speed, with AI spending hitting...

OPRX : 8.24 (-10.73%)
CTSH : 65.97 (-6.97%)
CERT : 6.55 (-5.48%)
OABI : 1.6350 (-3.82%)
ALEN-U.CN : 1.2100 (-3.20%)
OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance

-   Q3 revenue of $26.1 million, increased 22% year-over-year -   Q3 gross profit increased 30% year-over-year to $17.5 million -   Increases full year 2025 guidance to a revenue range between $105...

OPRX : 8.24 (-10.73%)
OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 2025, at 4:30 p.m. ET

WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and...

OPRX : 8.24 (-10.73%)
OptimizeRx to Participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference

WALTHAM, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and...

OPRX : 8.24 (-10.73%)
OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising

Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood ® Targeting Data with Lamar’s Vast Nationwide OOH Network to  Strengthen OOH Media for Healthcare Marketing WALTHAM,...

OPRX : 8.24 (-10.73%)
LAMR : 132.37 (-0.20%)
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and...

OPRX : 8.24 (-10.73%)
OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

Q2 revenue of $29.2 million, increased 55% year-over-year Q2 gross profit increased 59% year-over-year to $18.6 million Paid down $4.5 million of principal on outstanding term loan during Q2 Increased...

OPRX : 8.24 (-10.73%)

Business Summary

OptimizeRx Corporation provides consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products. It offers pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. The Company offers...

See More

Key Turning Points

3rd Resistance Point 11.32
2nd Resistance Point 10.84
1st Resistance Point 10.03
Last Price 8.24
1st Support Level 8.74
2nd Support Level 8.26
3rd Support Level 7.45

See More

52-Week High 22.25
Fibonacci 61.8% 15.28
Fibonacci 50% 13.12
Fibonacci 38.2% 10.97
Last Price 8.24
52-Week Low 3.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar